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ABSTRACT
Background: Hepatitis B virus (HBV) genotypes and mutations are gaining importance in determin-
ing the clinical course of chronic liver disease.
Objectives: To determine and compare the distribution of HBV genotypes and genomic variations in 
Pakistan to other parts of the world.
Patients and Methods: We conducted a prospective study at Aga Khan University Hospital from De-
cember 2006 to December 2008. HBV genotype was determined in 257 HBV DNA-positive patients. 
Patients were divided into two groups according to HBeAg positivity. Mutations in the pre-core and 
core promoter regions of HBV were determined in HBeAg-negative patients by line probe INNOLIPA 
assay.
Results: The mean±SD age of patients was 28±5 years; there were 201 (78%) men. HBeAg was positive 
in 219 (85%) patients and negative in 38 (15%). HBeAg-positive patients were younger than HBeAg-
negative patients (95% vs 21% in ≤30 years, p<0.001). HBV genotype D found in 247 (96.2 %) patients 
followed by a combined infection with HBV genotype B+D in 9 (3.3%) and 1 (0.5%) with genotype A. 
The mutations identified in 38 HBeAg-negative patients were T1762/A1764 in 21 (55.2%), PC mutant in 
7 (18.4%), T1762/A1764/PC mutant in 2 (5%) and T1762/A1764/PC wild mutation in 1 (2%); no mutation 
identified in 7 (18.4%). Phylogenetic analysis did not show any significant differences between HBV 
genotype D isolated from Pakistan and those isolated from other parts of the world.
Conclusions: HBV genotype D is predominant in Pakistan, irrespective of HBeAg status. PC and BCP 
mutations were found in significant numbers of patients infected with genotype D. The HBV geno-
type D isolates from Pakistan are identical to the sequences isolated from other parts of the world.
  Implication for Health policy/practice/research/medical education: 
This study magnifies is an interesting article which describes the distribution of different genotypes and mutations of Hepatitis B virus among a 
normal population in Pakistan. Epidemiologists, basic sciences specialists like geneticians benefit from the results of this article. 
  Please cite this paper as:
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Background
The complete nucleotide sequence analysis of hepatitis B vi-
rus (HBV) shows an inter-group divergence of >8%, and an in-
tra-group divergence of <5.6% (1). Based upon this inter-group 
divergence and complete nucleotide sequencing, HBV has tra-
ditionally been classified into eight genotypes (A to H) (2, 3). In 
addition to these acknowledged genotypes, there are putative 
genotypes that could not be classified into any of the above-
mentioned groups; such variants include genotype I (4) and J (5, 
6). HBV genotypes are known to have a distinct pattern of geo-
graphic distribution: Genotype A is found in North America and 
northern Europe, as well as in some parts of Africa (7), whereas 
genotypes B and C are common in Southeast Asia and genotype 
D is found universally (8). Genotype E has been reported from 
western and South-east Africa (7). Genotype F has been detected 
in South and Central America (7) and genotype G has been re-
ported in France and North America (2). The data on distribu-
tion of HBV genotype is still emerging from South-east Asia. The 
most predominant genotype reported from India is genotype D 
(around 79%), followed by C (30%) (9); while in Iran genotypes 
D is reported as the most common HBV strains (10). The expres-
sion of anti-HBeAb with the disappearance of HBeAg is accom-
panied by emergence of different types of mutants in the ge-
nome of HBV. The most common mutants are pre-core (PC) and 
basal core promoter (BCP) and their appearance is heralded by 
an increase in the viral load and virulence. Like HBV genotypes, 
HBV mutant species like the PC mutants also seem to have a par-
ticular distribution, being more frequent in geographic regions 
such as Asia and the Mediterranean basin, where genotypes B, 
C and D are predominant and are rare in North America and 
Europe, where genotype A is commonly found (11, 12). In studies 
from Europe, differences among HBV genotypes in the selection 
of BCP and/or PC mutations and disease progression have been 
demonstrated (13). In the Asian context, studies provide strong HBV genotypes in pakistan Mumtaz K et al. 15
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evidence that HBV genotype B is associated with less active and 
insidious progressive liver disease compared with genotype C, 
but the basis for the difference in pathogenicity has not been de-
termined. Further studies are needed to delineate the relation 
between other HBV genotypes and course and outcomes of HBV 
infection (14). HBsAg, anti-HBe, and HBV DNA positive serologi-
cal profile can also be related to mutations affecting the BCP, es-
pecially A1762T and G1764A. PC and BCP mutations are found in 
isolation or with each other; mostly these mutation are related 
to HBeAg-negative phenotypes. These mutations have been as-
sociated with active hepatitis, severe disease after liver trans-
plantation, development of HCC and FHF (11, 15). There are stud-
ies from Pakistan reporting variable HBV genotypes and their 
frequencies; one study by Idress, et al, reported a predominance 
of genotype C, Alam, et al, found genotype D in 85%, Baig, et al, 
reported genotype D in 64% of patients (16-18) and Abbas, et al, 
reported genotype D as the predominant genotype; this study 
however, mostly included hemodialysis patients with HBV in-
fection (19).
Objectives
These studies are conducted on a local population with small 
sample size, and resulted in conflicting results and used less 
sensitive methods of genotyping. Henceforth, there is need to 
confirm these finding in a larger cohort. The objective of our 
study was to determine the country-wide distribution of HBV 
genotypes in Pakistan and the different HBV mutations in pa-
tients with HBeAg-negative infections. We also aimed at com-
pare the nucleotide sequence of HBV isolates from Pakistan to 
those isolated from other parts of the world.
Patients and Methods
Patients
The study population consisted of 257 patients with chronic 
hepatitis  B  infection  who  were  also  HBV  DNA  positive,  from 
all over the country diagnosed between December 2006 and 
December 2008. Blood samples were taken from patients who 
were selected by purposive convenient random sampling. The 
study samples were collected consecutively from various loca-
tions distributed widely in different parts of Pakistan so that 
they could reflect the distribution of HBV genotype in our coun-
try. The data on age, gender, HBeAg status and residential place 
of patients was included in the analysis to document the epide-
miology of HBV mutants in the country.
Serological and Biochemical analysis
The study population was tested for HBsAg, HBeAg, hepatitis B 
core IgM antibody (anti-HBc IgM) (Abbott EIA assay Chicago, IL, 
USA), HCV antibody and anti-HDV (Abbott Anti-Delta EIA assay, 
Chicago, IL, USA). Liver function tests including total bilirubin, 
alanine aminotransferase (ALT) and alkaline phosphatase lev-
els, serum albumin and prothrombin time were checked using 
a fully automated analyzer. In our laboratory the upper normal 
limit for ALT was 33 IU/mL for women and 55 IU/mL for men.
Nested PCR forDetection of HBV DNA
HBV DNA was extracted from 200 μL of serum using QIAmp 
DNA Blood Mini Kit (Qiagen, Inc., Hilden, Germany) and ampli-
fied for complete genome by previously reported primers (20). 
Contamination-free  environment  was  ensured  by  adequate 
physical separation of pre- and post-amplification areas. Prior 
to HBV RNA PCR assay, work bench was cleaned with DNA/RNA 
free wipes (Molecular Bioproducts, San Diego, CA, USA). Samples 
were then extracted and amplified in physically separate areas. 
Gloves were frequently changed during processing and aerosol 
barrier tips were used for setting up HBV RNA PCR assay. In addi-
tion, in each run no template controls were included for moni-
toring cross contamination.
Genotyping of HBV
We used commercially available Line Probe Assays for HBV 
genotyping (INNOGENETICS, Belgium) (21). To confirm the find-
ings, PCR products of three randomly selected samples were 
sequenced directly for complete genome with the prism Big 
Dye (Applied Biosystems, Foster City, CA) in an ABI 3100 DNA au-
tomated sequencer. Sequences obtained were analyzed in both 
forward and reverse directions. Complete genomes were assem-
bled using GENETYX version 11.0 (GENETYX, Tokyo, Japan). The 
sequences for phylogenetic analysis were retrieved from DDBJ/
EMBL/GenBank corresponding to the accession numbers men-
tioned in the tree. Alignment was accomplished using CLUSTAL 
W and NJ tree was constructed with Tamura-Nei distance correc-
tion model.
HBV Mutations
All patients with HBeAg-negative infection were analyzed for 
viral mutations in the PC and BCP regions. Commercially avail-
able Line Probe Assays for HBV mutation analysis (INNOGENET-
ICS,  Belgium)  (22)  was  used  for  this  purpose.  INNO-LiPA  Pre-
Core kit detects mutations in PC codon 28, and BCP A1762T and 
G1764A. The kit can detect a wild type/mutant mixed population 
of circulating virus.
Ethics
The study was approved by Ethical Review Committee, Aga 
Khan University Hospital, Karachi, Pakistan.
Statistical Analysis
The data are presented as mean±SD. The data were analyzed 
by SPSS release 16 (SPSS, Chicago, IL, USA) using x2, Student’s t 
tests and Fisher’s exact test when appropriate. A p<0.05 was con-
sidered statistically significant.
Results
Demographic profile
The mean±SD age of patients was 28±7 years. Patients con-
sisted of 201 (78%) men and 56 (22%) women (Table 1). HBeAg was 
positive in 219 (85%) patients suggesting they possibly had wild 
type of HBV infection; HBeAg was negative in 38 (15%). The large 
majority of patients with wild type of HBV infection (n=208; 
95%) were <30 years of age compared to those with HBeAg-neg-
ative infection (n=8; 21%) (p<0.001). The mean serum ALT level 
was not statistically different in HBeAg-positive compared to 
HBeAg-negative patients (103 vs 96 IU/mL) (Table 1).
Hepatitis B virus genotypes
Of the 257 patients studied, there were 150 from Sind, 50 from 16
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Punjab, 37 from Baluchistan and 20 from North-west frontier 
province (NWFP). Of these, 247 (96%) had HBV genotype D infec-
tion and 9 (3.5%) had a mixed genotype B+D infection. There was 
only one patient with genotype A infection. Out of 247 patients 
with genotype D chronic hepatitis B infection, 217 (87.8%) had 
HBeAg-positive infection while 30 (12.2%) had a mutant infec-
tion. We were able to demonstrate that eight (89%) of nine pa-
tients with mixed B+D HBV infection had wild type of HBV infec-
tion and only one had mutant infection.
Phylogenetic Analysis
Phylogenetic analysis revealed HBV genotype D (two with sub-
genotype D1 and one with sub-genotype D3) in the three random-
ly selected samples, showing concordance with the genotyping 
results by Inno Lipa. Isolates did not segregate on phylogenetic 
analysis from the reference isolates in comparison, also suggest-
ing that Pakistan isolates have the closest match from neighbor-
ing countries India and China in both D1 and D3 sub-genotypes 
(Figure 1). The nucleotide sequence data reported in this paper 
appear in the DDBJ/EMBL/GenBank nucleotide sequence data-
bases  with  the  accession  numbers:  AB583679,  AB583680,  and 
AB583681.
HBV Mutations in HBeAg-negative patients
There were 38 patients with HBeAg negative status in our study 
group. Mutations were detected in 31 (81.5%) patients in different 
PC or BCP regions. The details of these mutations identified in 
the study are shown in Table 2. In analysis of three complete ge-
nomes for genomic variations, with the reference sequences re-
trieved from database, it was found that the case Pkst8216 (sub-
genotype D1) had point mutations A1727G, T1653C and A1757G in 
addition to the BCP double mutation T1762/A1764 and PC stop 
codon mutation A1896. The same case also had a pre-S deletion 
of 48 nucleotides between 2999-3047. The other two cases did 
not show any specific genomic variations in comparison to the 
reference sequences in comparison.
Discussion
We reported on a comprehensive country-wide report describ-
ing the prevalence of HBV genotypes and mutations in Pakistan. 
It is also confirming the phylogenetic analysis of hepatitis B 
reported by Baig, et al, (18) by full HBV genomic sequence from 
Pakistan. We found that genotype D was the predominant geno-
type in Pakistani patients with chronic HBV infection regardless 
of their HBeAg status. Mixed infection with genotypes B and D 
was present in a small percentage (3.5%) of patients; only one 
had genotype A infection. The mutation BCP A1762T and G1764A 
was found to be the most common mutation among HBeAg-
negative patients. The knowledge and determination of HBV 
genotypes is gaining clinical and epidemiologic significance. 
There are reports suggesting that evolution of HBV into differ-
ent genotypes probably started approximately 3000 years ago, 
by assuming the rate of nucleotide substitution at 1.4–3.2×105 
per site per year. It is a known fact that the rate of nucleotide 
substitution per site per year remains almost constant, as long 
as the gene function remains unchanged (23). Genotype D is 
considered to be the oldest type as it is originally widely distrib-
uted in the old world. High prevalence of genotype D may be as-
sociated with the old history of civilization in our region (24). In 
addition to the age of a civilization, HBV belonging to the same 
genotype are believed to have an evolutionary relationship, and 
have been used for tracing the route of HBV transmission and 
geographical migration of subjects with chronic HBV infection. 
The uniformity of infection with genotype D virus suggests a 
possible similar source of infection in our patient population 
(24).  The  importance  of  geographical  distribution  is  further 
supported by the presence of similar genotype in the adjacent 
areas of Pakistan, i.e., northern India, where genotype D is re-
ported in 46% of HBV patient population (25). Furthermore, 92% 
of western India (26) and 75% of southern India has the similar 
genotype distribution (27). We found mixed B+D HBV genotypes 
infection in nine patients, most of whom had wild type of HBV 
infection. Recombination between HBV genomes of two geno-
types (22, 28) and co-infection with more than one genotype may 
also be present in some patients. Genotypes of HBV have variable 
implications in selecting the patients for treatment. The results 
of studies with standard interferon (IFN) reported a favorable 
response to genotype C as compared to B (41% vs 15%) (29). The 
results of HBV genotype for pegylated IFN are variable; Cooksley, 
et al, (30) showed improved response rate in genotypes B vs C 
(33% vs 21%); another study, however, did not find any difference 
(HBeAg seroconversion at the end of 24-week post-treatment 
follow-up) among viral genotypes: Genotype A (52%), genotype 
B (30%), genotype C (31%) and genotype D (22%) (31). Nonetheless, 
overall, HBV genotype D is considered the least responsive of 
the major HBV genotypes to IFN therapy. The majority of stud-
ied patients in this study had HBeAg-positive infection; 15% had 
HBeAg-negative infection. This could be due to the fact that the 
majority of HBeAg-positive patients were young (<30 yrs of age); 
this figure could have been different in an older cohort. Almost 
all of our patients had more than one mutant infection except 
  
Table 1. Characteristic features of patients with HBV infections
Characteristics   HBeAg Positive  HBeAg Negative  p-value
    n=219    n=38
Male/Female   170/49    30/8    NS a
Mean age (yr)   27    28    NS a
    <30 years   155    8    <0.001
    >30 years   64    30   
Serum biliruin         1.2±0.9    1.3±0.7    NS a
(mg/dL)    
Serum ALT b    103±36    110 ±28     NS a
(IU/mL) (Mean±SD)         
Serum      101±12       92±07    NS a
alkaline phosphates
(IU/mL) (Mean±SD) 
Serum albumin    3.8±1.0    3.6±1.1    NS a
(g/dL)     
Genotypes    
    D     212    35    0.003
    B+D     7    1 
    A     0    2 
a  NS: Not Significant
b  ALT: Alanine aminotransferase
Table 2. Details of pre-core (PC) and basal core promotor (BCP) mutations as 
detected by line probe assays in HBeAg-negative patients (n=38)
   Mutation        n (%)
PC mutations alone      7 (18%)
BCP T 1762 +A 1764        21 (55%)
BCP T 1762 + A 1764 + PC mutant    2 (5%)
BCP T1762 +A 1764 + PC wild      1 (3%)
No mutation        7 (18%)HBV genotypes in pakistan Mumtaz K et al. 17
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seven with PC codon 28 infection alone. Fifty-five percent of our 
patients had dual BCP A1762T and G1764A infection. It is reported 
that these mutants mostly produce chronic hepatitis followed 
by self-limited hepatitis or asymptomatic carrier status (32). It is 
also reported that dual mutations can enhance the viral replica-
tion (28). We used line probe assay for detecting mutations. This 
test was however, unable to detect any mutations in 18% of our 
patients. There is a possibility of detecting more mutants with 
the help of direct sequence analysis as shown by Davidson, et al. 
He compared the line probe assay with direct sequence analy-
sis and found that it is more sensitive in detecting mixed infec-
tion in patients with genotype D (22, 24). Similarly, Maisa Ali, et 
al, compared INNO-LiPA HBV assay, direct DNA sequencing and 
subtractive PCR-RFLP or genotyping of clinical HBV isolates in 
80 patients and found that the PCR-RFLP-based method incor-
rectly identified some genotype D strains (33). Most of the previ-
ous studies reported from Pakistan have used PCR-RFLP meth-
ods  and  that  is  why  they  under-reported  genotype  D  (16-18). 
Our results indicated that genotype D is the predominant HBV 
genotype in Pakistan, and perhaps in South Asia, as indicated by 
studies from India. This should be kept in mind when consider-
ing treatment options for chronic HBV patients in this region. 
A considerable number of our patients with HBeAg-negative in-
fection had PC and BCP mutations; mutations at multiple sites 
were common. Sequencing and phylogenetic analysis of HBV 
genotype D isolate in three of our patients was not different 
from HBV genotype D isolates from other parts of world.
Figure 1. Phylogenetic tree of sub-genotypes of human HBV isolates from Pakistan
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